Pseudogene-mediated DNA demethylation leads to oncogene activation

Area of Science:

• Epigenetics
• Cancer Biology
• Genomics

Background:

• Pseudogenes, noncoding gene homologs, were historically considered evolutionary relics.
• Emerging evidence links pseudogenes to cancer prognoses and subtypes, yet their roles remain largely uncharacterized.
• Over 12,000 human pseudogenes exist, with limited understanding of their functional significance in oncogenesis.

Purpose of the Study:

• To investigate the unrecognized role of pseudogenes as epigenetic regulators in cancer.
• To explore the function of pseudogenes in the activation of oncogenes, specifically SALL4 in hepatocellular carcinoma (HCC).
• To elucidate the mechanism by which pseudogenes influence oncogene expression and its clinical relevance.

Main Methods:

• Utilized locus-specific demethylating technology to identify critical regulatory regions for oncogene expression.
• Investigated the interaction between SALL4 pseudogene 5 and DNMT1 (DNA methyltransferase 1).
• Analyzed pseudogene and oncogene expression in a hepatitis B virus (HBV) model and in patients with HBV-associated HCC.

Main Results:

• Identified a critical CpG region regulating SALL4 expression in HCC.
• Demonstrated that SALL4 pseudogene 5 actively hypomethylates this region via DNMT1 interaction, leading to SALL4 up-regulation.
• Observed significant up-regulation of pseudogene 5 preceding SALL4 induction in an HBV model, with both elevated in HBV-HCC patients.

Conclusions:

• Pseudogenes can function as potent epigenetic regulators, actively demethylating and activating oncogenes.
• Pseudogene-mediated demethylation represents a novel mechanism for oncogene activation in cancer.
• The SALL4 pseudogene 5-DNMT1 interaction highlights a new pathway in HBV-associated HCC pathogenesis.